Using the 99DOTS (directly observed treatment, short course) application for improved adherence to tuberculosis treatment in Namibia: A mixed-methods study
DOI:
https://doi.org/10.7196/SAMJ.2025.v115i6.2623Keywords:
Operational research, infectious diseases, indigenous populations, San, NamibiaAbstract
Background. In Namibia, community-based directly observed tuberculosis (TB) treatment (C-DOT) has been effective for individuals living in settled villages, but it is problematic for mobile indigenous people who survive through hunting and gathering and have among the highest TB and multidrug-resistant TB rates and lowest adherence to TB treatment globally.
Objectives. The 99DOTS (directly observed treatment, short course) programme was piloted in the Tsumkwe Healthcare Centre and the 25 villages in the catchment area from quarter 2, 2019 to quarter 1, 2020. Programme staff facilitated and monitored TB treatment adherence.
Methods. Twenty patients and two healthcare workers who managed the patients were interviewed on treatment completion using a semi- structured interview process.
Results. Respondents were of low socioeconomic status; many were not schooled and not employed, and few had a monthly household income >NAD100 (USD5.50). According to the programme server reports, only six of the respondents did not miss any doses of their TB treatment, although few doses were missed proportionally. Most respondents reported a supportive family structure and health system, with treatment support given by families and regular follow-up by health workers. Positive feedback was received about use of the 99DOTS application; respondents found the application easy to use and did not mind using it in front of other people, in and out of their homes.
Conclusion. 99DOTS was a feasible, innovative and accessible treatment adherence component integrated directly into the existing C-DOT approach. National TB programmes in similar high-burden settings could consider this approach to improve adherence.
References
1. RuswaN,MavhungaF,RoscoeJC,etal.Secondnationwideanti-tuberculosisdrugresistancesurvey in Namibia. Int J Tuberc Lung Dis 2019;23(7):858-864. https://doi.org/10.5588/ijtld.18.0526
2. World Health Organization. Global tuberculosis report 2022. 27 October 2022. https://www.who. int/publications/i/item/9789240061729 (accessed 16 November 2022).
3. World Health Organization. Ending tuberculosis (TB) a priority for Namibia. 12 April 2024. https:// www.afro.who.int/countries/namibia/news/ending-tuberculosis-tb-priority-namibia (accessed 13 August 2024).
4. National Tuberculosis and Leprosy Programme, Namibia. Survey to determine the prevalence of bacteriologically confirmed pulmonary tuberculosis among adults (15 years old and above) in Namibia. NTLP, 2017.
5. MinistryofHealthandSocialServices,RepublicofNamibia.Communicablediseases.https://mhss. gov.na/disease (accessed 13 August 2024).
6. Howell EM, Kigozi NG, Heunis JC. Community-based directly observed treatment for TB patients to improve HIV services: A cross-sectional study in a South African province. BMC Health Serv Res 2018;18(1):255. https://doi.org/10.1186/s12913-018-3074-1
7. Amnesty International. Namibia: Discrimination deprives indigenous San people of the right to health as TB poses serious risk to their lives. 6 October 2021. https://www.amnesty.org/en/latest/ news/2021/10/namibia-discrimination-deprives-indigenous-san-people-of-the-right-to-health-as- tb-poses-serious-risk-to-their-lives/ (accessed 19 November 2022).
8. GibsonD.NegotiatingthesearchfordiagnosisandhealingtuberculosisinNamibia:Acasestudyof a Ju/’hoansi speaking man. Afr Sociol Rev 2010;14(2):47-61.
9. Uukunde P, Mungunda H, Ruswa N, Mavhunga F, Platt G, Goenka A. Management of drug- resistant TB among the San community in Namibia: A call for community engagement. National Tuberculosis and Leprosy Programme, Namibia, 2011.
10. Anderson L, Levy J, Snow K. Epidemiological review of TB disease in Namibia. National Tuberculosis and Leprosy Programme, Namibia, 2016.
11. Ministry of Health and Social Services, Namibia. National Tuberculosis and Leprosy Programme Annual Report 2015-2016. MHSS, 2016.
12. ThakkarD,PiparvaK,LakkadS.Apilotproject:99DOTSinformationcommunicationtechnology- based approach for tuberculosis treatment in Rajkot district. Lung India 2019;36(2):108-111. https:// doi.org/10.4103/lungindia.lungindia_86_18
13. Thomas BE, Vignesh Kumar J, Onongaya C, et al. Explaining differences in the acceptability of 99DOTS, a cell phone-based strategy for monitoring adherence to tuberculosis medications: Qualitative study of patients and health care providers. JMIR Mhealth Uhealth 2020;8(7):e16634. https://doi.org/10.2196/16634
14. Thomas BE, Kumar JV, Chiranjeevi M, et al. Evaluation of the accuracy of 99DOTS, a novel cellphone-based strategy for monitoring adherence to tuberculosis medications: Comparison of digital adherence data with urine isoniazid testing. Clin Infect Dis 2020;71(9):e513-e516. https:// doi.org/10.1093/cid/ciaa333
15. Prabhu A, Agarwal U, Tripathy JP, et al. ‘99DOTS’ techno-supervision for tuberculosis treatment – a boon or a bane? Exploring challenges in its implementation at a tertiary centre in Delhi, India. Indian J Tuberc 2020;67(1):46-53. https://doi.org/10.1016/j.ijtb.2019.08.010
16. KNCVTuberculosefonds.Riziki:‘IencourageanyTBpatienttouse99DOTSiftheycan’.19October 2020. https://www.kncvtbc.org/en/2020/10/19/riziki-i-encourage-any-tb-patient-to-use-99dots-if- they-can/ (accessed 15 December 2020).
17. Adherence Support Coalition to End TB. ‘99DOTS digital technology helped me get cured of TB’. 14 August 2020. https://www.digitaladherence.org/storyofangelito/ (accessed 15 December 2020).
18. Ministry of Health and Social Services, Namibia. Third Medium Term Strategic Plan for Tuberculosis and Leprosy 2017/18-2021/22. 2017. https://policyvault.africa/policy/third-medium- term-strategic-plan-for-tuberculosis-and-leprosy-2017-18-2021-22/ accessed 3 June 2025).
Downloads
Published
Issue
Section
License
Copyright (c) 2025 M Claassens, P Steenkamp, R Gavioli, T Woldetsadik
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
